Tourmaline Bio Statistics

Total Valuation

Tourmaline Bio has a market cap or net worth of $511.20 million. The enterprise value is $241.41 million.

Market Cap	511.20M
Enterprise Value	241.41M

Important Dates

The next estimated earnings date is Thursday, August 7, 2025, before market open.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Tourmaline Bio has 25.69 million shares outstanding. The number of shares has increased by 144.29% in one year.

Current Share Class	25.69M
Shares Outstanding	25.69M
Shares Change (YoY)	+144.29%
Shares Change (QoQ)	-0.40%
Owned by Insiders (%)	8.46%
Owned by Institutions (%)	64.28%
Float	13.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.75
P/TBV Ratio	1.75
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 33.87, with a Debt / Equity ratio of 0.00.

Current Ratio	33.87
Quick Ratio	32.71
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -26.14% and return on invested capital (ROIC) is -19.39%.

Return on Equity (ROE)	-26.14%
Return on Assets (ROA)	-19.03%
Return on Invested Capital (ROIC)	-19.39%
Return on Capital Employed (ROCE)	-35.17%
Revenue Per Employee	n/a
Profits Per Employee	-$1.12M
Employee Count	74
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +27.40% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+27.40%
50-Day Moving Average	16.00
200-Day Moving Average	19.40
Relative Strength Index (RSI)	71.83
Average Volume (20 Days)	360,832

Short Selling Information

The latest short interest is 3.08 million, so 12.01% of the outstanding shares have been sold short.

Short Interest	3.08M
Short Previous Month	3.26M
Short % of Shares Out	12.01%
Short % of Float	22.20%
Short Ratio (days to cover)	9.33

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-98.45M
Pretax Income	-35.69M
Net Income	-82.87M
EBITDA	-98.41M
EBIT	-98.45M
Earnings Per Share (EPS)	-$3.22

Full Income Statement

Balance Sheet

The company has $249.31 million in cash and $196,000 in debt, giving a net cash position of $249.11 million or $9.70 per share.

Cash & Cash Equivalents	249.31M
Total Debt	196,000
Net Cash	249.11M
Net Cash Per Share	$9.70
Equity (Book Value)	279.86M
Book Value Per Share	10.90
Working Capital	250.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$84.02 million and capital expenditures -$18,000, giving a free cash flow of -$84.04 million.

Operating Cash Flow	-84.02M
Capital Expenditures	-18,000
Free Cash Flow	-84.04M
FCF Per Share	-$3.27

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Tourmaline Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-144.29%
Shareholder Yield	-144.29%
Earnings Yield	-16.89%
FCF Yield	-17.13%

Dividend Details

Analyst Forecast

The average price target for Tourmaline Bio is $49.33, which is 147.89% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$49.33
Price Target Difference	147.89%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	42.77%
EPS Growth Forecast (5Y)	0.48%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a